Merck & Co. Stock News

Merck remains a top Big Pharma brand with strong management, expected sales growth, and high profit margins, helped by the revolutionary Keytruda invention.

Merck & Co., Inc.'s heavy reliance on Keytruda continues to grow, with the drug nearing 50% of total sales and limited growth from other products. Valuation has become attractive after a significant share price pullback, now trading at just 10x adjusted earnings and offering a 4% dividend yield. Despite expensive M&A and some new product launches, non-Keytruda sales remain flat, highlighting th...

Although Merck (NYSE:MRK) is confronted with the unavoidable Keytruda patent cliff in 2028, the company is strategically positioning itself for further growth by diversifying and expanding its pipeline. Earlier this month, we highlighted how Keytruda is a ticking time bomb for Merck stock.

Health and Human Services (HHS) Secretary Robert F. Kennedy Jr., who has previously made statements skeptical of vaccines, is now recommending the respiratory syncytial virus (RSV) vaccine for infants.On Thursday, RFK's Advisory Committee on Immunization Practices (ACIP) voted to recommend clesrovimab, a new RSV antibody shot made by Merck, for infants 8 months and younger who don't have protec...

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--ACIP Recommends Merck's ENFLONSIA for Prevention of RSV in Infants Younger than 8 Months of Age Born During or Entering Their First RSV Season.

Health and Human Services Secretary Robert F. Kennedy Jr.'s revamped government panel of vaccine advisors recommended the use of Merck's shot designed to protect infants from respiratory syncytial virus during their first season of the virus.

An advisory panel of the U.S. Centers for Disease Control and Prevention on Thursday recommended the use of Merck's respiratory syncytial virus therapy, Enflonsia, for infants 8 months or younger, whose mother did not receive a preventive shot during pregnancy.

The S&P 500 flirted with bear-market territory earlier this year. Although it has mostly recovered, plenty of companies are still dealing with issues that have led to poor performances.